<DOC>
	<DOCNO>NCT01906658</DOCNO>
	<brief_summary>This 8-week randomized , open-label evaluation examine acute safety tolerability 4 different dose regimen Acthar inform dose selection future study Acthar patient Amyotrophic Lateral Sclerosis ( ALS ) . The study also investigate mean rate change ALSFRS-R total score exploratory endpoint help design future study . This study enroll 40 patient include optional 28-week open-label extension period plus 3-week treatment taper 1-week follow period . After completion Week 8 , patient enrol treatment group consider safe tolerable time option continue open-label extension period . A 3-week treatment taper follow-up visit plan patient enrol study , begin either Week 8 Week 36 patient continue optional open-label extension period .</brief_summary>
	<brief_title>A Study Explore Safety Tolerability Acthar Patients With Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>Able provide inform consent . Diagnosis clinically definite ALS , clinically probablelaboratory support ALS , clinically probable ALS , clinically possible ALS base revise El Escorial criterion . Patients ALS ≤ 3 year since symptom onset . Symptom onset defined date first muscle weakness dysarthria . Upright slow vital capacity ( SVC ) ≥ 60 % predict . If take riluzole and/or Nuedexta® , stable regimen require ≥ 30 day prior screen . Medically ( either independently caregiver assistance ) able comply study procedure , include subcutaneous ( SC ) injection study medication adherence concomitant medication restriction . Any medical condition know association motor neuron dysfunction might confound obscure diagnosis ALS . Tracheostomy , diaphragm pacing , ongoing need assist ventilation type ( e.g. , bilevel positive airway pressure ) treatment ALSrelated respiratory dysfunction ( vital capacity &lt; 60 % predict , nocturnal desaturation , and/or nocturnal hypoventilation ) . Patients assisted ventilation reason require approval Medical Monitor . ( Supplemental oxygen acceptable ) . Recorded diagnosis evidence major psychiatric disorder . Clinically evident cognitive and/or behavioral impairment opinion Investigator would impair ability patient comply study procedure . Therapies and/or Medications : 1 . History prior sensitivity Acthar porcine protein product . 2 . Chronic systemic corticosteroid use , define &gt; 20 mg prednisone equivalent systemic corticosteroid take 4 consecutive week within 6 month prior randomization . Topical , inhale , intraarticular corticosteroid allow . 3 . Planned treatment live live attenuate vaccine enrol study . Participation another therapeutic ( drug device ) investigational study within 30 day prior screen . Type 1 type 2 diabetes mellitus , patient currently take hypoglycemic medication . Contraindication per Acthar Prescribing Information , Appendix D Section 4 : scleroderma , osteoporosis , systemic fungal infection , ocular herpes simplex , recent surgery , history presence peptic ulcer , congestive heart failure , uncontrolled hypertension , primary adrenocortical insufficiency , adrenal cortical hyperfunction . 1 . For purpose study , osteoporosis define history lumbar spine and/or femoral neck Tscore ≤ 2.5 bone densitometry ( DXA ) , OR osteoporosis require pharmacologic therapy , OR history nontraumatic low impact hip vertebral fracture , OR patient report history osteoporosis . 2 . For purpose study , history peptic ulcer define ≤ 6 month prior screen . 3 . For purpose study , uncontrolled hypertension define mean systolic blood pressure ≥ 140 mmHg diastolic blood pressure ≥ 90 mmHg ≥ 3 seated reading take least 5 minute apart screen period . 4 . For purpose study , congestive heart failure define New York Heart Association Functional Class IIIIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>H.P . Acthar Gel</keyword>
	<keyword>Acthar</keyword>
	<keyword>amyotrophic lateral sclerosis</keyword>
	<keyword>ALS</keyword>
</DOC>